Skip to main content
Premium Trial:

Request an Annual Quote

Karo Bio Implements TurboWorx Workflow Automation Software

NEW YORK, Nov. 4 (GenomeWeb News) - TurboWorx today said that Swedish drug discovery firm Karo Bio has purchased the TurboWorx suite of workflow automation software products.

TurboWorx said that Karo Bio has deployed the TurboWorx products in its Linux computing environment, which includes Linux workstations and a Linux cluster. The company is using the software to develop, automate, execute, and share scientific computational workflows in its computational biology and chemistry groups.

Karo Bio's modeling group plans to use the TurboWorx software to automate sequence alignments and load them into the Karo Bio Internal Target (KBIT) database. The group also plans to automate common modeling tasks such as virtual screening, combinational library design, and the batch calculation and loading of property predictions.

Financial terms of the licensing agreement were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.